China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ)
- Previous Close
31.07 - Open
30.70 - Bid 31.21 x --
- Ask 31.25 x --
- Day's Range
30.64 - 31.48 - 52 Week Range
22.91 - 38.98 - Volume
4,754,105 - Avg. Volume
5,964,035 - Market Cap (intraday)
15.773B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
72.74 - EPS (TTM)
0.43 - Earnings Date Apr 23, 2024
- Forward Dividend & Yield 0.30 (0.96%)
- Ex-Dividend Date Apr 26, 2024
- 1y Target Est
35.03
China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the blood products, and biochemical and chemical drugs businesses in China and internationally. It offers blood products comprising human fibrinogen, intravenous human immunoglobulin, rabies immunoglobulin, human albumin, and human immunoglobulin; non-blood products, including metformin hydrochloride enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glipizide tablets, glimepiride tablets, pioglitazone hydrochloride dispersible tablets, simvastatin tablets, and calcium dobesilate capsules. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co., Ltd. The company was founded in 1993 and is based in Fuzhou, China.
www.china-boya.comRelated News
Performance Overview: 300294.SZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300294.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300294.SZ
Valuation Measures
Market Cap
15.77B
Enterprise Value
10.23B
Trailing P/E
72.74
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.91
Price/Book (mrq)
2.11
Enterprise Value/Revenue
4.46
Enterprise Value/EBITDA
31.52
Financial Highlights
Profitability and Income Statement
Profit Margin
9.55%
Return on Assets (ttm)
3.94%
Return on Equity (ttm)
3.03%
Revenue (ttm)
2.29B
Net Income Avi to Common (ttm)
219.17M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
5.57B
Total Debt/Equity (mrq)
0.33%
Levered Free Cash Flow (ttm)
348.38M
Research Analysis: 300294.SZ
Company Insights: 300294.SZ
300294.SZ does not have Company Insights